CJC-1295 Ipamorelin UK – Research Peptide
Anglo Peptides presents
CJC-1295 Ipamorelin as a research-focused peptide
combination intended for legitimate laboratory and scientific research.
The product brings together two distinct compounds that have been
investigated in relation to growth-hormone signalling and the
GH-IGF-1 axis.
CJC-1295 is a long-acting analogue associated with
growth hormone-releasing hormone (GHRH) signalling, while Ipamorelin is a
synthetic growth hormone secretagogue. Their different molecular
characteristics make the combination relevant to experimental research
into endocrine signalling and peptide pharmacology.
This page is provided for scientific and product information only. It
does not provide human dosing instructions, administration protocols,
treatment recommendations or guidance for personal use.
What Is CJC-1295 Ipamorelin?
CJC-1295 Ipamorelin refers to a combination of two
separate research peptides rather than a single molecular compound.
CJC-1295 was developed as a long-acting GHRH analogue. Human research has
examined its pharmacokinetics and its effects on circulating growth
hormone and IGF-1.
Ipamorelin is a pentapeptide belonging to the growth hormone secretagogue
family. Experimental pharmacology research has demonstrated selective
growth hormone-releasing activity through a GHRP-like receptor.
Researchers should therefore consider the pharmacology of each peptide
individually when evaluating a combination product.
The original scientific characterisation of Ipamorelin is available through
PubMed’s Ipamorelin research
.
CJC-1295 Research Profile
CJC-1295 peptide research has focused substantially on
growth hormone and IGF-1 signalling.
In a randomised, placebo-controlled study in healthy adults, CJC-1295
produced sustained, dose-dependent increases in circulating GH and IGF-1
under the conditions examined. The study also characterised the compound’s
prolonged pharmacokinetic profile.
Additional research found that CJC-1295 could increase GH secretion while
maintaining aspects of the hormone’s pulsatile pattern.
Researchers can review the
CJC-1295 human pharmacology study
for further scientific information. :contentReference[oaicite:1]{index=1}
Ipamorelin Research Profile
Ipamorelin peptide research has focused on its activity
as a selective growth hormone secretagogue.
Early experimental studies found that Ipamorelin stimulated growth hormone
release in pituitary cell systems and animal models. Its pharmacological
profile differed from several earlier secretagogues because of its
relative selectivity for GH release.
Human pharmacokinetic and pharmacodynamic research has also examined the
relationship between circulating Ipamorelin concentrations and GH
responses in healthy volunteers.
A human pharmacokinetic study is available through
PubMed’s Ipamorelin pharmacokinetic research
. :contentReference[oaicite:2]{index=2}
CJC-1295 Ipamorelin and Growth Hormone Signalling
The scientific interest in CJC-1295 Ipamorelin research
comes from the different signalling characteristics of the two peptides.
CJC-1295 is associated with GHRH-related signalling, whereas Ipamorelin
acts as a growth hormone secretagogue. Studying these pathways provides
researchers with a model for examining different mechanisms involved in
the regulation of GH secretion.
The broader GH-IGF-1 axis is involved in multiple physiological processes,
including growth, metabolism and tissue biology. CJC-1295 and Ipamorelin
have consequently attracted research interest within endocrinology and
peptide pharmacology.
A recent 2026 review discusses both CJC-1295 and Ipamorelin among
experimental peptides affecting the GH-IGF-1 axis and highlights the
limitations surrounding unregulated peptide products. :contentReference[oaicite:3]{index=3}
CJC-1295 and Ipamorelin: Key Differences
| Research characteristic | CJC-1295 | Ipamorelin |
|---|---|---|
| Peptide classification | GHRH analogue | Growth hormone secretagogue |
| Primary research interest | GH and IGF-1 signalling | GH release |
| Research history | Human and preclinical studies | Human and preclinical studies |
| Molecular identity | Distinct synthetic peptide | Distinct synthetic pentapeptide |
These differences are important when interpreting research. Results
involving one compound should not automatically be attributed to the
other.
Research Applications of CJC-1295 Ipamorelin
Research involving the two compounds can cover a range of scientific
topics, including:
- Growth hormone signalling
- GH-IGF-1 axis research
- GHRH receptor biology
- Growth hormone secretagogue activity
- Endocrine signalling
- Peptide pharmacology
- Pharmacokinetic research
- Receptor-ligand interactions
These are areas of scientific investigation rather than approved medical
indications.
CJC-1295 Ipamorelin UK Product Information
Researchers searching for CJC-1295 Ipamorelin UK should
review the product specifications on this page before ordering.
Relevant considerations may include the exact formulation, individual
peptide quantities, product presentation, storage information where
supplied and applicable fulfilment arrangements.
Researchers should verify the exact composition and analytical
documentation associated with the material being evaluated before
incorporating it into a laboratory protocol.
For delivery information, see the
Anglo Peptides Shipping Policy
.
Interpreting Combination Peptide Research
One important consideration when evaluating CJC-1295 Ipamorelin is the
distinction between evidence for individual peptides and evidence for the
complete combination.
CJC-1295 has its own pharmacological literature, while Ipamorelin has been
investigated independently. Findings from those studies cannot
automatically establish that combining the two compounds produces an
additional or synergistic biological effect.
Experimental results may also vary according to peptide purity,
formulation, concentration, sequence, research model and analytical
methodology.
Researchers should therefore assess primary literature alongside
product-specific documentation.
Current Research and Safety Considerations
CJC-1295 and Ipamorelin remain subjects of experimental peptide research.
They should not be presented as established treatments or approved
medicines based solely on their research history.
A 2026 review of GH-axis peptides notes that CJC-1295 and Ipamorelin are
among compounds marketed as research peptides and highlights concerns
regarding limited clinical evidence, product quality and safety
uncertainties. :contentReference[oaicite:4]{index=4}
Researchers should use appropriate laboratory controls and institutional
safety procedures when working with experimental peptide materials.
Related CJC-1295 and Ipamorelin Products
Researchers who want to compare related formulations can explore other
CJC-1295 and Ipamorelin products within the Anglo Peptides catalogue.
CJC-1295 Ipamorelin
– another combination research listing.
CJC-1295 Ipamorelin 10/10mg
– a separately listed formulation.
Ipamorelin
– a standalone Ipamorelin research product.
CJC-1295 + Ipamorelin
– another related combination page.
Browse the complete
research peptide collection
for additional laboratory materials.
Ordering CJC-1295 Ipamorelin UK
Before ordering, researchers should review the available product
information and confirm that the intended purchase is appropriate for
legitimate laboratory or scientific research.
Customers and researchers are responsible for ensuring that their
purchase, possession, handling and intended research activities comply
with applicable laws, regulations and institutional requirements.
Visit the
Anglo Peptides Shop
to explore additional research materials.
Research-Use Notice
CJC-1295 Ipamorelin products supplied through Anglo Peptides are presented
strictly for legitimate research purposes.
This product is not intended for human consumption, self-administration,
diagnosis, treatment or prevention of disease.
Anglo Peptides does not provide human dosing instructions, administration
protocols, treatment recommendations or medical advice. Researchers are
responsible for ensuring that their activities comply with applicable
legal, regulatory and institutional requirements.
Frequently Asked Questions
What is CJC-1295 Ipamorelin?
CJC-1295 Ipamorelin refers to a combination of two distinct research
peptides: CJC-1295, a GHRH analogue, and Ipamorelin, a growth hormone
secretagogue.
What is CJC-1295 researched for?
CJC-1295 has been investigated in relation to growth hormone and IGF-1
secretion, pharmacokinetics and GHRH-related signalling. :contentReference[oaicite:5]{index=5}
What is Ipamorelin researched for?
Ipamorelin has been investigated as a selective growth hormone
secretagogue and in studies examining GH release and pharmacokinetics.
:contentReference[oaicite:6]{index=6}
Are CJC-1295 and Ipamorelin the same peptide?
No. They are chemically different peptides with different
pharmacological characteristics and signalling mechanisms.
Does research prove that the combination is synergistic?
Not conclusively. Research on the individual compounds should not be
interpreted as proof that combining them produces a clinically established
synergistic effect.
Is CJC-1295 Ipamorelin an approved medicine?
This product is presented as experimental research material and should not
be represented as an approved medicinal product.
Is this product intended for human use?
No. Products supplied through Anglo Peptides are presented strictly for
legitimate research purposes and are not intended for human consumption
or self-administration.
Where can I find related products?
Explore the
Ipamorelin research product
or browse the complete
research peptide collection
.
Explore CJC-1295 Ipamorelin UK
Review the available CJC-1295 Ipamorelin information and explore related
research materials through the Anglo Peptides catalogue.
Reviews
There are no reviews yet.